IDE892 as monotherapy and in combination with IDE397 in patients with 5-methylthioadenosine phosphorylase-deleted (MTAP-Del) advanced solid tumors (IDE892001): Phase 1 trial. This is an ASCO Meeting ...
A phase 3 randomized, open-label study of pasritamig (JNJ-78278343), a T-cell engager targeting human kallikrein-2, with docetaxel versus docetaxel for metastatic castration-resistant prostate cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results